Home / Biosimilars / General / Biosimilars approved in the US
Biosimilars approved in the US Posted 14/08/2015

Last update: 31 August 2018 In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).
The BPCI Act is part of the healthcare reform legislation, which was signed into law on 23 March 2010 by President Barack Obama. The BPCI Act establishes an abbreviated approval pathway for biological products that are demonstrated to be ‘highly similar’ (biosimilar) to, or ‘interchangeable’ with, a US Food and Drug Administration (FDA)-licensed biological product. FDA is still in the process of developing guidelines regarding these types of products and has issued several guidance documents on the subject [1]. Zarxio (filgrastim-sndz) was the first product approved in the US as a biosimilar in 2015 [2]. To date, FDA has approved 12 biosimilars within the product classes of anti-tumour necrosis factor-alpha (TNF-α), HER2/neu and granulocyte colony-stimulating factor, and two follow-on biologicals in the product class of insulin for use in the US, see Table 1. The agency has also granted tentative approval to an insulin glargine follow-on biological, pending patent litigation. Table 1: FDA approved biosimilars and follow-on biologicals* Product name Active substance Therapeutic area Authorization date Manufacturer/ Company name Admelog# insulin lispro Diabetes 11 Dec 2017 Sanofi Amjevita (adalimumab-atto) adalimumab
Ankylosing spondylitis 23 Sep 2016 Amgen Basaglar# insulin glargine Diabetes 16 Dec 2015
Eli Lilly/ Cyltezo (adalimumab-adbm) adalimumab
Ankylosing spondylitis 25 Aug 2017 Boehringer Ingelheim Erelzi (etanercept-szzs) etanercept
Axial spondyloarthritis 30 Aug 2016 Sandoz Fulphila (pegfilgrastim-jmdb) pegfilgrastim Febrile neutropenia 4 Jun 2018 Biocon/Mylan
Inflectra infliximab
Ankylosing spondylitis 5 Apr 2016 Pfizer (Hospira) Ixifi (infliximab-qbtx) infliximab
Ankylosing spondylitis 13 Dec 2017 Pfizer Lusduna# (tentative approval) insulin glargine Diabetes 20 Jul 2017 Merck Mvasi (bevacizumab-awwb) bevacizumab
NSCLC 14 Sep 2017 Amgen/Allergan Nivestym (filgrastim-aafi) filgrastim
Autologous peripheral blood progenitor cell collection and therapy 20 Jul 2018 Pfizer (Hospira) Ogivri (trastuzumab-dkst) trastuzumab
HER2 breast cancer 1 Dec 2017 Biocon/Mylan Retacrit (epoetin alfa-epbx) epoetin alfa
Anaemia (chronic kidney disease, Zidovudine, chemotherapy) 15 May 2018 Pfizer (Hospira) Renflexis (infliximab-abda) infliximab
Ankylosing spondylitis 21 Apr 2017 Samsung Bioepis
Zarxio filgrastim
Autologous peripheral blood progenitor cell collection and therapy 6 Mar 2015 Sandoz
*Data updated 31 August 2018 The landmark decision by FDA to approve its first biosimilar came in the wake of a unanimous vote two months earlier by FDA advisors who recommended approval of Zarxio [3]. Sandoz, the generics division of Novartis, already markets its biosimilar filgrastim product under the brand name Zarzio in more than 40 countries outside the US [4]. All the products approved so far have been approved as biosimilars, not as interchangeable products. According to the BPCI Act, only a biological that has been approved as interchangeable may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. FDA has designated placeholder non-proprietary names for Amjevita, Cyltezo, Erelzi, Fulphila, Inflectra, Ixifi, Mvasi, Nivestym, Ogivri, Renflexis, Retacrit and Zarxio: adalimumab‑atto, adalimumab‑adbm, etanercept‑szzs, pegfilgrastim-jmdb, infliximab‑dyyb, infliximab-qbtx, bevacizumab-awwb, filgrastim-affi, trastuzumab-dkst, infliximab-abda, epoetin alfa-epbx and filgrastim‑sndz, respectively. The agency issued final guidance on the naming of biologicals in January 2017 [5].
Related articles
References Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Boehringer Ingelheim
Crohn’s disease
Juvenile arthritis
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Polyarticular juvenile idiopathic arthritis
Psoriatic arthritis
Plaque psoriasis
Rheumatoid arthritis
(infliximab- dyyb)
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Colorectal neoplasms
Renal cell carcinoma
Ovarian neoplasms
Breast neoplasms
Bone marrow transplantation
Cancer
Myeloid leukaemia
Neutropenia
HER2 metastatic gastric or gastroesophageal junction adenocarcinoma
Reduction of allogeneic red blood cell transfusions
Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
(filgrastim-sndz)
Bone marrow transplantation
Cancer
Myeloid leukaemia
Neutropenia
#Admelog, Basaglar and Lusduna were approved via the FDA’s abbreviated 505(b)(2) pathway as follow-on products not as biosimilars. No insulin lispro or glargine products were licensed under the Public Health Service Act at the time of filing, so there was no ‘reference product’ for a proposed biosimilar product.
NSCLC: Non-Small-Cell Lung Carcinoma.
Biosimilars approved in Europe
1. GaBI Online - Generics and Biosimilars Initiative. US guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Guidelines/US-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves its first biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-its-first-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. FDA advisers recommend approval of filgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-advisers-recommend-approval-of-filgrastim-biosimilar
4. GaBI Online - Generics and Biosimilars Initiative. FDA accepts biosimilar filgrastim application [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 14]. Available from: www.gabionline.net/Biosimilars/News/FDA-accepts-biosimilar-filgrastim-application
5. GaBI Online - Generics and Biosimilars Initiative. FDA issues final guidance on naming biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Feb 9]. Available from: www.gabionline.net/Guidelines/FDA-issues-final-guidance-on-naming-biologicals
Source: US FDA
Comments (3)
Response to ‘Biosimilars’ posted 18/03/2016 posted 05/10/2016 - by Louis B, GaBI Online Editorial Office
Dear Kauntay Parekh, thank you for your valid and interesting comment on this article. Thank you for sharing your thoughts on this subject. We would be delighted if you would consider submitting a short Commentary paper on this topic to GaBI Journal. Please feel free to reach us at editorial@gabi-journal.net for further information. Thank you again and we hope to hear from you soon. Best regards, Louis.Biosimilars posted 05/10/2016 - by Kauntay Parekh
Hi, Hemanth Kumar, 1. How many phase I, II, III trials are needed to be conducted for a Biosimilar in US and EU? Ans: In US and EU, biosimilar applicant has to discuss with drug regulatory authority to decide the clinical trial (CT) pathway for the particular product (For US FDA and for EU EMA). These regulatory authority devise the CT pathway based on the products similarity with reference biologic (Based on analytical data). Overall, the more similar the biosimilar product to reference product based on analytical data, the lesser CT will be required. 2. What is the trial duration for these trials (In general)? Ans: Trial duration varies from product to product but generally these trials get completed within 2-4 years. 3. How the development timelines and trial size differ for biosimilars from their reference biologic drugs? Ans: Unlike reference product sponsor, biosimilar applicant has to prove similarity, efficacy, safety and toxicity data comparable to reference biologic. Hence, the CT size required for biosimilar is smaller than the reference biologic.Biosimilars posted 02/09/2015 - by Hemanth Kumar G
Dear Sir/Madam, Thank you very much for your articles and news about Biosimilars and generics world at gabionline. I observed from one of your articles that it takes less than 2 years for completion of Biosimilar pivotal trials, I have a few queries regarding that. 1. How many phase I, II, III trials are needed to be conducted for a Biosimilar in US and EU? 2. What is the trial duration for these trials (In general) ? 3. How the development timelines and trial size differ for Biosimilars from their reference biologic drugs? I would be grateful if you can answer these queriesGenerics News Research General
- Safety surveillance of bevacizumab biosimilar (...Generics/Research | Posted 15/02/2019
- European regulatory framework for approval of b...Generics/Research | Posted 15/02/2019
- Impact of generic reference pricing on candesar...Generics/Research | Posted 15/02/2019
- Zydus gets FDA approval for skin, heart and aci...Generics/News | Posted 15/02/2019
Biosimilars News Research General
- PanGen gains Malaysian approval for epoetin alf...Biosimilars/News | Posted 15/02/2019
- Long-term stability of trastuzumab biosimilar u...Biosimilars/Research | Posted 08/02/2019
- Barriers and facilitators to biosimilar prescri...Biosimilars/Research | Posted 08/02/2019
- Liability chain of biosimilar switchingBiosimilars/Research | Posted 01/02/2019